Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Sun Pharmaceutical Industries Q2 FY 24 consolidated PAT higher at Rs. 2375.51 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023

Briefs: Sun Pharmaceutical Industries and Dr. Reddy’s

Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.

Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr

The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)

Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients

Sun Pharma settles patent litigation with Incyte

Briefs: Hikal and Sun Pharma

Sun Pharma gets 8 observations from USFDA for Halol facility